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Resumen
Introducción y objetivos: conocer la prevalencia de sobrepeso y obesidad, así como su asociación con la función pulmonar, el colesterol total 
y la vitamina D en pacientes con fi brosis quística (FQ).
Material y métodos: estudio multicéntrico descriptivo y transversal. Participaron 12 hospitales españoles. Fueron incluidos 451 pacientes con 
FQ, clasifi cados según el índice de masa corporal (IMC) en adultos y el IMC percentilado (tablas OMS) en niños. Análisis estadístico: C.Pearson, 
Anova, t de Student y regresión lineal múltiple. 
Resultados: la mediana de edad fue 12,3 (rango 4-57) años. Un 51% eran varones y el 18%, sufi cientes pancreáticos (SP). El 12% estaba 
desnutrido; el 57%, en riesgo nutricional; el 24%, normonutrido; el 6% presentaba sobrepeso; y un 1%, obesidad. La función pulmonar en los 
pacientes con sobrepeso (91 ± 19%) era mejor que en los desnutridos (77 ± 24%) (p = 0,017), sin embargo, no se observaron diferencias con 
respecto a los que estaban en riesgo nutricional (86 ± 19%) o normonutridos (90 ± 22%). Los pacientes con sobrepeso tenían más elevado el 
colesterol total (p = 0,0049), mayor proporción de hipercolesterolemia (p = 0,001), así como niveles más bajos de 25 OH vitamina D (p = 0,058).
Conclusiones: la prevalencia de sobrepeso y obesidad fue del 6 y el 1%. El sobrepeso y la obesidad no ofrecen benefi cio sobre la función 
pulmonar en comparación con los normonutridos. 
Abstract
Introduction: The primary objective of this study was to fi nd out the prevalence of overweight and obese status, as well as their association to 
pulmonary function, total cholesterol and vitamin D in patients with cystic fi brosis (CF). 
Materials and methods: This is a multicenter descriptive and cross-sectional study. Twelve Spanish hospitals participated. 451 patients with 
CF were included. Adults were classifi ed according to body mass index (BMI) and children were classifi ed according to BMI percentiles (WHO 
tables). Pearson’s correlation, Anova, Student’s t-test and multiple linear regression were conducted. 
Results: Mean age was 12.3 (range 4-57) years old, 51% were male and 18% had pancreatic suffi ciency. Participants were classifi ed in fi ve 
nutritional status categories: 12% were malnourished; 57%, at nutritional risk; 24%, normally nourished; 6%, overweight; and 1%, obese. 
Pulmonary function in overweight or obese patients (91 ± 19%) was better than in malnourished patients (77 ± 24%) (p = 0.017). However, no 
difference was observed between those at nutritional risk (86 ± 19%) or normally nourished (90 ± 22%) groups. Overweight and obese patients 
had higher levels of total cholesterol (p = 0.0049), a greater proportion of hypercholesterolemia (p = 0.001), as well as lower levels of 25 OH 
vitamin D (p = 0.058).
Conclusions: Prevalence of overweight and obese was 6 and 1%. Excess weight status does not offer any benefi t in pulmonary function in 
comparison to normally nourished patients. 
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INTRODUCTION
Advances in early diagnosis and comprehensive treatment of 
cystic fibrosis (CF) have caused an increase in the survival of 
these patients (1). One of the factors that has contributed to this 
phenomenon has been the improvement of the nutritional status 
through intensive nutritional intervention based on hypercaloric 
diets and nutritional supplements, as well as enteral nutrition and 
pancreatic enzymes for the control of steatorrhea. 
On the other hand, patients with CF are not free from the pre-
vailing sedentariness in our current society, which, combined to 
the improvements in medical and nutritional treatment, has led 
to the existence of a potential risk for excessive weight gain in 
some of these patients.
There are few data regarding the actual prevalence of over-
weight in CF. Recently published studies in Toronto and the USA 
indicate a prevalence of overweight between 15 and 18% (in 
children and adults respectively) and up to 8% for obesity (2,3). 
Obesity is widely recognized as an important risk factor for the 
development of metabolic complications such as insulin resis-
tance, hypertension, and dyslipidemia, which may increase the 
risk of cardiovascular diseases and type 2 diabetes. However, the 
presence of these obesity-related metabolic disturbances varies 
widely among obese individuals. Accordingly, a unique subset of 
obese individuals has been described in the medical literature 
that appears to be protected or more resistant to the develop-
ment of metabolic abnormalities associated with obesity. These 
individuals, now known as “metabolically healthy but obese”, 
despite having excessive body fatness, display a favorable meta-
bolic profile characterized by high levels of insulin sensitivity, no 
hypertension, as well as normal lipid, inflammation, hormonal and 
immune profiles (4).
In contrast to the general population, CF patients who are 
overweight or obese have good pulmonary function (5). However, 
recent studies suggest that after certain thresholds, body mass 
index (BMI) is inversely correlated with pulmonary function (6). On 
the other hand, the effects of excess weight at the cardiovascular 
level are unknown in this population. For CF patients, absolute 
BMI should be maintained at or above 22 kg/m2 in females and 
23 kg/m2 in males. For children, the 50th percentile is optimal (7).
The objective of our study was to establish the prevalence of 
overweight and obese status, as well as its association with pul-
monary function, vitamin D and total cholesterol in our population 
of CF patients.
MATERIALS AND METHODS 
This is a multicenter descriptive and cross-sectional study that 
was done from November 1st 2012 to April 30th 2014 during 
the months of November to April (when vitamin D levels were 
at nadirs). Clinically stable CF patients over four years old, in 
absence of pulmonary exacerbation, in 12 Spanish university hos-
pitals were enrolled. Ethical approval was granted by the Ethics 
Committee of the Principality of Asturias, reference number (no. 
45/15). Patients and guardians received written, complete and 
detailed information of the study, and all of them signed their 
informed consent for the study. All patients were treated according 
to published European CF guidelines (8).
Each patient was identified with a code assigned to the hospital 
and the case. Information was taken from the patients’ medical 
files.
The date of birth, gender, race, the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene genetic test, as well 
as whether they had been diagnosed using neonatal screening, 
were also recorded.
The investigators measured the morning weight and height, 
patients being barefoot and in underwear, using instruments with 
a precision of 50 g and 0.5 cm respectively, and calculated BMI. 
All somatometric data were classified (z-score) according to the 
WHO references (9). The nutritional status of each patient was 
classified according to the BMI in adults (≥ 18 years old) and the 
BMI percentile in children, as follows: malnourished (< 18.5 kg/
m2, < P10), nutritional risk (18.5-21.9 kg/m2 for female, 18.5-
22.9 for male kg/m2; P10-p49), normally nourished (22-24.9 kg/
m2 for female, 23-24.9 kg/m2 for male; P50-84), overweight (25-
29.9 kg/m2, P85-94) and obese (≥ 30 kg/m2, ≥ P95). Those with 
growth failure were also considered as malnourished (height < 
P3) (8,10).
Pancreatic function was established with the determination of 
fecal elastase-1 (E-1) levels. Information was taken from the med-
ical file of the patients. Those with concentrations less than 200 
μg/g were considered to have pancreatic insufficiency (PI) (11). 
The daily dose of vitamin D received by patients was quantified 
in IU/day. Vitamin D levels in the form of serum 25 OH vitamin D 
were measured by chemiluminescence immunoassays (CLIA) in 
each hospital. Levels of 25 OH vitamin D less than 30 ng/ml and 
20 ng/ml were considered to be insufficient and as deficiency, 
respectively (12). Total cholesterol levels were quantified in mg/dl 
form and hypercholesterolemia was considered when levels were 
above 200 mg/dl. The measurements were taken while fasting.
Pulmonary function was analyzed as the forced expiratory 
volume in the first second of expiration (FEV1) using forced spi-
rometry. Percentages were calculated from the absolute values 
expected for healthy individuals with the same age, gender and 
height as the patient (13).
The data collected were exported to a statistical data manage-
ment program (STATA version 13.0). Basic statistical techniques 
for descriptive analysis were applied for the study. Pearson and 
Spearman correlation tests were used to analyze the joint behav-
ior of the quantitative variables. Two-tailed t-tests were used for 
comparison of the averages of two groups, as well as one-fac-
tor ANOVA and Bonferroni post-hoc tests for comparison of the 
averages of three or more groups. For comparison of proportions, 
Chi-squared tests were used. To analyze the association between 
nutritional status, FEV1, cholesterol and 25 OH vitamin D, a linear 
regression analysis was conducted with multivariate adjustment 
(by sex, age, PI, CFTR gene, screening). If some of the variables 
did not meet some of the requirements of normality, non-para-
metric tests were applied (Mann-Whitney test). The differences 
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were considered as statistically significant when the probability 
value was p < 0.05.
RESULTS
DESCRIPTIVE CHARACTERISTICS
A total of 451 patients with CF aged 4-57 years old (median age 
[Md] 12.3 years old) were included in this study. Table I shows the 
main anthropometric characteristics and data of the 451 patients 
analyzed. 
NUTRITIONAL STATUS
When analyzing the nutritional status of our patients according to 
BMI and height, 12% were malnourished, 57% were at nutritional 
risk, 24% were normally nourished, 6% were overweight and 1% 
were obese. If we use BMI as the only nutritional criterion, two of 
the patients classified as normally nourished (0.5%) and 14 of the 
patients classified as being at nutritional risk (3%) must be classified 
as malnourished given that their height was less than P3. 
Patients who were overweight or obese (excess weight group) 
were between five and 49 years old, with a Md of 12 and an 
interquartile range (IQR) between ten and 16 years. Twenty-seven 
per cent were homozygous carriers of the DF508 mutation, 43% 
were heterozygous carriers and 30% were not carriers of said 
mutation on any of their alleles. Fifty-two per cent were males. The 
age, gender distribution and genetic background of the patients 
who were overweight or obese were similar to those of the rest 
of the sample. A greater proportion of pancreatic sufficient (PS) 
was observed, 55% vs 15% (p < 0.001), as well as a lower 
proportion of patients receiving vitamin D supplements, 76% vs 
93% (p < 0.001). 
Regarding vitamin D, 8% of patients, all of them pancreatic 
sufficient, did not receive daily supplementation. In those who 
received it, the median dose was 962 IU/day of vitamin D (IQR 
800-1,600 IU/day). 
NUTRITIONAL STATUS AND PULMONARY 
FUNCTION
In pediatric patients, an association was observed between BMI 
(z score) and FEV1 (%) (r = 0.250, p < 0.001) (Fig. 1). Pulmonary 
function in patients who were excess weight (overweight or obese) 
(91 ± 19%) was better than in malnourished patients (77 ± 24%) 
(p = 0.017). However, differences were not observed between 
excess weight and those who were at nutritional risk (86 ± 19%) 
or normally nourished (90 ± 22%) (Fig. 2). 
The association between nutritional status and FEV1 was ana-
lyzed using a linear regression analysis. The variables that were 
kept in the model were: male gender; age; PS and malnutrition 
(Table II).
TOTAL CHOLESTEROL AND VITAMIN D  
IN OVERWEIGHT CF PATIENTS
Levels of total cholesterol were between 58 and 265 mg/dl, 
with a Md of 130 mg/dl (IQR 111-152.5 mg/dl). Only 5% of the 
patients had levels of total cholesterol above 200 mg/dl. Thir-
ty-three per cent of obese patients had hypercholesterolemia; Md 
Table I. Main features and anthropometric data of 451 patients analyzed
Variable
EPI
371
PS
80
Total 
451
Sex (% women) 49 50 49
Age (Md [range]; year) 12.2 (4 to 56) 12.9 (5 to 57) 12.3 (4 to 57) 
Group age
 < 18 years (%)
 ≥ 18 years (%)
86
14
86
14
85
15
CFTR mutation
 Homozygous DF508 (%)
 Heterozygous DF508 (%)
 No DF508 (%)
40
47
13
0
65
35
33
50
17
Newborn screening (% yes) 36 39 37 
Vitamin D dose (Md [interquartile range]) (Ui/day) 1,000 (800-1,600) 756 (400-1,150) 962 (800-1,600)
BMI (Md [interquartile range])
 < 18 years (z score)
 ≥ 18 years (kg/m2)
-0.43 (-0.87 to 0.05) 
21.5 (19.7 to 23.3)
-0.03 (-0.48 to 1.05)
24.6 (19.4 to 25.6)
-0.37 (-0.8 to 0.12) 
21.6 (19.8 to 23.7) 
PS: Pancreatic sufficiency; EPI: Exocrine pancreatic insufficiency.
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pared with non-overweight neither obese had elevated levels of 
total cholesterol: 154 ± 8 vs 130 ± 1 mg/dl (p = 0.0049) and 
a greater proportion of hypercholesterolemia 16% vs 3% (p = 
0.001). However, those associations were not maintained in the 
multivariate analysis (Table III). 
Levels of vitamin D were between five and 95 ng/ml with a Md 
of 26 ng/ml (IQR 20-33.5 ng/ml). Sixty-four per cent had insuf-
ficient levels, and 25% of these had levels lower than 20 ng/ml. 
In obese, the Md was 23 ng/ml (IQR 22-25 ng/ml). The patients 
who were excess weight compared with non-overweight neither 
obese had lower levels of vitamin D (24 ± 2 vs 28 ± 1) ng/ml (p 
= 0.058). Adjusting for confounding factors and modifiers such 
as age, exocrine pancreatic function and vitamin D dose received, 
the patients who were overweight maintained lower levels of 25 
OH vitamin D but it was not statistically significant: b = -5.28 (CI 
95% -10.51 and 0.09) (p = 0.054) ng/ml.
DISCUSSION
Obesity and weight gain have become a genuine epidemic, 
whose prevalence has doubled in developed countries in the last 
20 years. In Spain, 30% of children between six and 12 years 
old are overweight, and 10% are obese (14). The phenomenon 
is primarily related to exogenous causes, such as an increase in 
energy consumed in the diet, combined with a reduction in the 
activities that involve energy expenditure and an increase in those 
of the sedentary type, and it is also associated with genetic and 
epigenetic factors. This tendency in lifestyle is not exclusive to the 
general population. It also affects patients with chronic diseases 
such as CF, probably with greater intensity.
In our study we observed that 7% of patients carried excess 
weight (6% overweight and 1% obese), about half the number of 
malnourished patients (12%), while the majority presented normal 
nutritional status. If we keep in mind the physiopathology of this 
disease, this prevalence seems to be elevated; however, our num-
bers are lower when we compare them to North American data, 
where prevalence reaches 23% (15% overweight and 8% obese) 
(3). These results could be explained by the differences in lifestyle 
and diet between both countries. There are also methodological 
Figure 1. 
Association between BMI (z score) and FEV1 (%) in childhood (< 18 years).
Figure 2. 
Lung function of patients ranked by nutritional status.
Table II. Results of multivariable linear regression for associations of subject characteristics 
with FEV1 % predicted
Variable Partial β coefficient (95% CI) p value R2 for multivariable model
0.25
Age -1.3 (-1.5 to -1.0) 0.000
Male 4.1 (0.5 to 7.6) 0.025
Pancreatic sufficient 5.5 (0.6 to 10.3) 0.028
Nutritional status (vs malnourished)
 Nutritional risk (BMI P10-49)
 Normo-nourished (BMI P50-P85)
 Overweight-obesity (BMI > P85) 
7.8 (2.1 to 13.5)
15.0 (8.7 to 21.4)
13.1 (4.3 to 21.9)
0.008
0.000
0.004
cholesterol in this group was 169 mg/dl (IQR 153-228 mg/dl). The 
proportion of hypercholesterolemia was greater in adult patients 
11% vs 3% (p = 0.003). Patients who were excess weight com-
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differences between the two analyses: in contrast to our study, 
the North American series only uses body mass index, without 
accounting for growth failure as a malnutrition criteria. Conse-
quently, patients who are actually malnourished could be cate-
gorized incorrectly as normally nourished or overweight. Another 
important factor could be age, excess weight is mostly described 
in adults CF patients with mild phenotypes and SP.
Advances in the genetic knowledge of this disease and the 
implementation of neonatal screening have allowed more frequent 
diagnosis of patients with less aggressive phenotypes and PS. In 
our study, the proportion of patients with PS was greater in those 
who were overweight or obese (> 50%), a fact already described 
by Stephenson et al. (2) in a longitudinal study in adults with 
CF, wherein overweight status is associated with PS, advanced 
age, good pulmonary function and male gender. These PI patients 
have energy requirements that are similar to those of the general 
population; however, the majority of guides do not make distinc-
tions, and specific nutritional recommendations do not exist for 
these types of patients. However, excess weight is not exclusively 
associated to milder clinical forms. In our case, more than 25% of 
patients who were overweight or obese were homozygous carriers 
of the DF508 mutation and presented exocrine pancreatic insuffi-
ciency (EPI). This circumstance was previously described by Kast-
ner-Cole (5) in a study conducted on 3,000 pediatric and adult 
patients who were homozygous carriers of the DF508 mutation, in 
which up to 9% were observed to be overweight and 1% obese.
The positive association between nutritional status and pulmo-
nary function is well-known in this disease. Additionally, in contrast 
to the general population, patients who are overweight and obese 
have good pulmonary function. In our analyses, we observe a pos-
itive association between BMI and FEV1, as well as the negative 
effect of malnutrition on pulmonary function. However, the patients 
who were overweight and obese did not have better pulmonary 
function than those who were normally nourished or at nutritional 
risk. Moreover, in the multivariate analysis we observed how, in 
those who maintained a BMI between P50 and P85, this had a 
superior effect on pulmonary function compared to those who 
were overweight or obese. Recent publications in adults suggest 
that the positive association between BMI and FEV1 is reversed 
from BMI values > 25 kg/m2 (2,6). On the other hand, it has 
been observed that the parameter best associated with pulmonary 
function, from the nutritional point of view in these patients, is 
the fat-free mass index (15,16). However, given the difficulties in 
accessing the body composition tests, we consider that the use 
of BMI between P50 and P85 as a nutritional objective can be 
helpful in usual clinical practice.
The association between overweight and obese status and vita-
min D deficiency has been described in the general population. 
The mechanism is not exactly known, but it is believed that it is 
due to the decrease in the bioavailability of vitamin D secondary to 
the increase in adiposity of obese patients (17). To our knowledge, 
to date vitamin D levels have not been analyzed in patients with 
CF and overweight or obese status. In our study we observe how, 
independently of factors that affect levels of vitamin D in this dis-
ease, such as exocrine pancreatic function, age, dose of vitamin 
D, and chronic inflammation (all were in absence of pulmonary 
exacerbation), patients with excess weight had an average of 5 
ng/ml less of 25 OH vitamin D (p = 0.054). Given the increase in 
the prevalence of overweight status in this disease, we consider 
that this is another factor that should be kept in mind when the 
serum levels of this fat-soluble vitamin are analyzed.
Cholesterol levels in patients with CF are generally lower 
compared to the general population. In our study, only 5% had 
hypercholesterolemia, with endocrine pancreatic function being 
the variable that best determined levels of cholesterol, in such a 
way that PS patients had between 21 and 36 mg/dl more total 
cholesterol than PI patients. These differences are explained pri-
marily because patients with PI, even when receiving enzyme 
supplementation, present fat malabsorption as well as greater 
chronic inflammation. The atherogenic lipid profile characterized 
by elevation of LDL cholesterol and the total cholesterol/HDL ratio 
has been observed in 50% of PS adult patients and up to 24% of 
IP patients (18). An association between BMI and LDL cholesterol 
in adult CF patients was recently described (19). Even though 
data on the HDL and LDL cholesterol fractions is not available, 
hypercholesterolemia values are above those published in our 
study, probably due to the lower age of our patients. 
Microvascular complications have been described in patients 
who presented cystic fibrosis-related diabetes (20). However, only 
isolated published cases of macrovascular complications in adults 
with CF are known (21). Even when receiving a hypercaloric diet 
(22), the apparent absence of atherosclerosis is explained by the 
low levels of cholesterol as well as by the difficulty patients have 
surviving into the 5th and 6th decade of life, the age at which peak 
incidence of these diseases occurs in the general population. 
However, the increase in life expectancy, as well as overweight 
Table III. Results of multivariable linear regression for associations of subject 
characteristics with total cholesterol
Variable Partial β coefficient (95% CI) p value R2 for multivariable model
0.23
Age 1 (0.6 to 1.3) 0.002
Male -7 (-13 to -2) 0.008
Pancreatic sufficient 29 (21 to 36) < 0.001
BMI > P50 7 (1 to 12) 0.028
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and obese status, and the presence of more atherogenic lipid 
profiles in patients with PS, must alert us to the risk of developing 
metabolic problems not described to date in patients with CF.
Our study is one of the broadest published to date that analyses 
the prevalence of overweight and obese status in pediatric and 
adult patients with CF, as well as the first to analyze the asso-
ciation between vitamin D and excess weight in these patients. 
Despite the results, we are conscious of the methodological lim-
itations of the study. The cross-sectional nature of this study does 
not allow us to conclude if the excess weight is the cause or the 
consequence. Nutritional evaluation with exclusively anthropo-
metric data does not provide exact information on the real body 
composition of the patients; however, in contrast to other projects, 
we have included the evaluation of height to avoid under-diag-
nosing malnutrition. The multicentric nature, while necessary to 
obtain a sufficient sample size in a low prevalence disease such 
as CF, together with the retrospective collection of the data, may 
cause bias when analyzing serum levels and somatometric data, 
but close follow-up at specific units for this disease considerably 
reduces these errors. Another limitation was the small number of 
adults enrolled. Nowadays, half of patients of CF units are adults 
and up to one third are diagnosed at this age group, so the prev-
alence of overweight and obese as well as hypercholesterolemia 
may be increased in next years.
In summary, in the last few years we have observed an increase 
in nutritional problems due to excess weight in patients with CF. 
The benefits for pulmonary function, when compared to normally 
nourished patients, do not appear to be as significant as it was 
initially thought. Dietary recommendations based on hypercaloric 
diets must continue to be the basis of nutritional support, however, 
they must be personalized according to the characteristics of the 
patient. If we do not keep these circumstances in mind, in the 
near future we could face the appearance of metabolic problems 
not described to date in patients with CF.
CONCLUSIONS 
Prevalence of overweight and obese was 6 and 1% respectively. 
Excess weight status does not offer any benefit in pulmonary 
function in comparison to normally nourished patients.
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